Pipeline
Glycostem’s pipeline has the potential to redefine standards of care across various type of cancer where there is an urgent medical need.
Therapy
Product
Indication
Cell
Development
Pre-clinical
Phase I
Phase II
Phase III
Partner
oNKord®
Inaleucel
AML
NK Cell
Phase I
medac (EU)
inno.N (Japan and Korea)
oNKord®
Inaleucel
AML
NK Cell
I
2025
medac (EU)
inno.N (Japan and Korea)
Inaleucel
Metastatic solid tumors
Combination Therapy: NK cell + mAb/ICE
Pre-clinical
oNKord®
Inaleucel
Metastatic solid tumors
Combination Therapy: NK cell + mAb/ICE
PRE
TBA
Inaleucel
Solid tumors (e.g. uCCLM)
NK Cell
Pre-clinical
oNKord®
Inaleucel
Solid tumors (e.g. uCCLM)
NK Cell
PRE
viveNK™
GTA103
OGD2+ Solid Tumors
CAR-NK
Pre-clinical
viveNK™
GTA103
OGD2+ Solid Tumors
CAR-NK
PRE
TBA
GTA103
N/A
CAR-NK
Development
viveNK™
GTA103
N/A
CAR-NK
DEV
TBA
GTA201
N/D
TCR-NK
Development
viveNK™
GTA201
N/D
TCR-NK
DEV
TBA
Therapy
Phase
Partner
oNKord®
Inaleucel
AML
NK Cell
Phase I
medac (EU)
inno.N (Japan and Korea)
oNKord®
Inaleucel
AML
NK Cell
I
2025
medac (EU)
inno.N (Japan and Korea)
Inaleucel
Metastatic solid tumors
Combination Therapy: NK cell + mAb/ICE
Pre-clinical
oNKord®
Inaleucel
Metastatic solid tumors
Combination Therapy: NK cell + mAb/ICE
PRE
TBA
Inaleucel
Solid tumors (e.g. uCCLM)
NK Cell
Pre-clinical
oNKord®
Inaleucel
Solid tumors (e.g. uCCLM)
NK Cell
PRE
viveNK™
GTA103
OGD2+ Solid Tumors
CAR-NK
Pre-clinical
viveNK™
GTA103
OGD2+ Solid Tumors
CAR-NK
PRE
TBA
GTA103
N/A
CAR-NK
Development
viveNK™
GTA103
N/A
CAR-NK
DEV
TBA
GTA201
N/D
TCR-NK
Development
viveNK™
GTA201
N/D
TCR-NK
DEV
TBA